CR10314A - Compuestos que tienen actividad en el receptor m 1 y sus usos en medicina - Google Patents
Compuestos que tienen actividad en el receptor m 1 y sus usos en medicinaInfo
- Publication number
- CR10314A CR10314A CR10314A CR10314A CR10314A CR 10314 A CR10314 A CR 10314A CR 10314 A CR10314 A CR 10314A CR 10314 A CR10314 A CR 10314A CR 10314 A CR10314 A CR 10314A
- Authority
- CR
- Costa Rica
- Prior art keywords
- compounds
- medicine
- receiver
- activity
- solvates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/26—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Se proporcionan compuestos de formula (I), sales y solvatos. Tambien se describen usos de los compuestos para terapia, por ejemplo en el tratamiento de trastornos psicoticos y deterioro cognitivo.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0605786.3A GB0605786D0 (en) | 2006-03-22 | 2006-03-22 | Compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
CR10314A true CR10314A (es) | 2008-12-01 |
Family
ID=36383995
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR10314A CR10314A (es) | 2006-03-22 | 2008-09-23 | Compuestos que tienen actividad en el receptor m 1 y sus usos en medicina |
Country Status (22)
Country | Link |
---|---|
US (3) | US20100280071A1 (es) |
EP (1) | EP2004182B1 (es) |
JP (1) | JP5256187B2 (es) |
KR (1) | KR20090015027A (es) |
CN (2) | CN101448495B (es) |
AR (1) | AR059977A1 (es) |
AU (1) | AU2007228716A1 (es) |
BR (1) | BRPI0708999A2 (es) |
CA (1) | CA2646896A1 (es) |
CR (1) | CR10314A (es) |
EA (1) | EA200870360A1 (es) |
GB (1) | GB0605786D0 (es) |
IL (1) | IL194206A0 (es) |
MA (1) | MA30324B1 (es) |
MX (1) | MX2008012160A (es) |
NO (1) | NO20084048L (es) |
NZ (1) | NZ595738A (es) |
PE (1) | PE20080007A1 (es) |
SG (1) | SG170752A1 (es) |
TW (1) | TW200813004A (es) |
WO (1) | WO2007107565A1 (es) |
ZA (1) | ZA200807616B (es) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0605785D0 (en) * | 2006-03-22 | 2006-05-03 | Glaxo Group Ltd | Compounds |
GB0706164D0 (en) * | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
GB0706174D0 (en) * | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
GB0706170D0 (en) * | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
GB0706187D0 (en) * | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
GB0706167D0 (en) * | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
TW200930367A (en) * | 2007-09-20 | 2009-07-16 | Glaxo Group Ltd | Compounds which have activity at M1 receptor and their uses in medicine |
JP2010539217A (ja) * | 2007-09-20 | 2010-12-16 | グラクソ グループ リミテッド | M1受容体にて活性を有する化合物および医薬としてのそれらの使用 |
WO2009124883A1 (en) * | 2008-04-09 | 2009-10-15 | H. Lundbeck A/S | Novel 1,3-dihydro-benzoimidazol-2-ones as m1 agonists |
GB0817982D0 (en) * | 2008-10-01 | 2008-11-05 | Glaxo Group Ltd | Compounds |
JP5990980B2 (ja) * | 2012-04-02 | 2016-09-14 | 大日本印刷株式会社 | オランザピンの中間体の製造方法 |
CN109069426B (zh) | 2015-12-14 | 2021-10-29 | X4 制药有限公司 | 治疗癌症的方法 |
WO2017106332A1 (en) | 2015-12-14 | 2017-06-22 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
DK3393468T3 (da) | 2015-12-22 | 2022-12-19 | X4 Pharmaceuticals Inc | Fremgangsmåder til behandling af en immundefektsygdom |
CN107129439A (zh) * | 2016-02-26 | 2017-09-05 | 中国科学院大连化学物理研究所 | 一种化合物、毒蕈碱m受体拮抗剂、组合物及应用 |
JP2019510785A (ja) | 2016-04-08 | 2019-04-18 | エックス4 ファーマシューティカルズ, インコーポレイテッド | 癌を処置する方法 |
JP7084624B2 (ja) * | 2016-06-21 | 2022-06-15 | エックス4 ファーマシューティカルズ, インコーポレイテッド | Cxcr4阻害剤およびその使用 |
ES2870920T3 (es) | 2016-06-21 | 2021-10-28 | X4 Pharmaceuticals Inc | Inhibidores de CXCR4 y usos de los mismos |
US11332470B2 (en) | 2016-06-21 | 2022-05-17 | X4 Pharmaceuticals, Inc. | CXCR4 inhibitors and uses thereof |
US10548889B1 (en) | 2018-08-31 | 2020-02-04 | X4 Pharmaceuticals, Inc. | Compositions of CXCR4 inhibitors and methods of preparation and use |
CN113637001A (zh) * | 2021-08-09 | 2021-11-12 | 安康市农业科学研究院 | 一种氟哌利多中间体的合成方法 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4040300A1 (de) * | 1990-12-17 | 1992-07-02 | Leifeld Gmbh & Co | Drueckmaschine mit wenigstens einem rollenhalter |
WO1996013262A1 (en) * | 1994-10-27 | 1996-05-09 | Merck & Co., Inc. | Muscarine antagonists |
WO1997016186A1 (en) * | 1995-10-31 | 1997-05-09 | Merck & Co., Inc. | Muscarine agonists |
JPH10330377A (ja) * | 1997-06-02 | 1998-12-15 | Kyowa Hakko Kogyo Co Ltd | ピペリジン誘導体 |
WO1999036421A1 (en) * | 1998-01-19 | 1999-07-22 | Pfizer Pharmaceuticals Inc. | 4-(2-keto-1-benzimidazolinyl)piperidine compounds as orl1-receptor agonists |
WO2001039775A1 (en) * | 1999-12-06 | 2001-06-07 | Euro-Celtique, S.A. | Benzimidazole compounds having nociceptin receptor affinity |
WO2004089942A2 (en) * | 2001-10-02 | 2004-10-21 | Acadia Pharmaceuticals Inc. | Benzimidazolidinone derivatives as muscarinic agents |
CA2488845A1 (en) * | 2002-06-17 | 2003-12-24 | Merck & Co., Inc. | Opthalmic compositions containing selective m1 muscarinic agonists for treating ocular hypertension |
JP2006511554A (ja) * | 2002-12-13 | 2006-04-06 | スミスクライン ビーチャム コーポレーション | Ccr5アンタゴニストとしてのピペリジン誘導体 |
US8288413B2 (en) * | 2005-09-30 | 2012-10-16 | Glaxo Group Limited | Benzimidazolones which have activity at M1 receptor |
-
2006
- 2006-03-22 GB GBGB0605786.3A patent/GB0605786D0/en not_active Ceased
-
2007
- 2007-03-20 EP EP07727115.3A patent/EP2004182B1/en active Active
- 2007-03-20 NZ NZ595738A patent/NZ595738A/xx not_active IP Right Cessation
- 2007-03-20 CA CA002646896A patent/CA2646896A1/en not_active Abandoned
- 2007-03-20 SG SG201102019-5A patent/SG170752A1/en unknown
- 2007-03-20 JP JP2009500852A patent/JP5256187B2/ja not_active Expired - Fee Related
- 2007-03-20 KR KR1020087025705A patent/KR20090015027A/ko not_active Application Discontinuation
- 2007-03-20 TW TW096109422A patent/TW200813004A/zh unknown
- 2007-03-20 WO PCT/EP2007/052638 patent/WO2007107565A1/en active Application Filing
- 2007-03-20 AU AU2007228716A patent/AU2007228716A1/en not_active Abandoned
- 2007-03-20 CN CN2007800188235A patent/CN101448495B/zh not_active Expired - Fee Related
- 2007-03-20 BR BRPI0708999-6A patent/BRPI0708999A2/pt not_active Application Discontinuation
- 2007-03-20 MX MX2008012160A patent/MX2008012160A/es not_active Application Discontinuation
- 2007-03-20 AR ARP070101119A patent/AR059977A1/es not_active Application Discontinuation
- 2007-03-20 EA EA200870360A patent/EA200870360A1/ru unknown
- 2007-03-20 US US12/293,625 patent/US20100280071A1/en not_active Abandoned
- 2007-03-20 PE PE2007000306A patent/PE20080007A1/es not_active Application Discontinuation
- 2007-03-20 CN CN2012102916757A patent/CN103058990A/zh active Pending
-
2008
- 2008-09-04 ZA ZA200807616A patent/ZA200807616B/xx unknown
- 2008-09-18 IL IL194206A patent/IL194206A0/en unknown
- 2008-09-23 CR CR10314A patent/CR10314A/es not_active Application Discontinuation
- 2008-09-23 NO NO20084048A patent/NO20084048L/no not_active Application Discontinuation
- 2008-10-07 MA MA31270A patent/MA30324B1/fr unknown
-
2011
- 2011-10-27 US US13/282,610 patent/US20120041028A1/en not_active Abandoned
-
2012
- 2012-08-14 US US13/584,956 patent/US20120316202A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
SG170752A1 (en) | 2011-05-30 |
MA30324B1 (fr) | 2009-04-01 |
JP5256187B2 (ja) | 2013-08-07 |
WO2007107565A1 (en) | 2007-09-27 |
IL194206A0 (en) | 2009-08-03 |
TW200813004A (en) | 2008-03-16 |
CN101448495A (zh) | 2009-06-03 |
EA200870360A1 (ru) | 2009-02-27 |
AU2007228716A1 (en) | 2007-09-27 |
MX2008012160A (es) | 2008-10-03 |
US20120316202A1 (en) | 2012-12-13 |
JP2009530347A (ja) | 2009-08-27 |
GB0605786D0 (en) | 2006-05-03 |
AR059977A1 (es) | 2008-05-14 |
BRPI0708999A2 (pt) | 2011-06-21 |
PE20080007A1 (es) | 2008-03-16 |
NZ595738A (en) | 2012-11-30 |
EP2004182B1 (en) | 2013-05-08 |
CN101448495B (zh) | 2013-05-08 |
CA2646896A1 (en) | 2007-09-27 |
KR20090015027A (ko) | 2009-02-11 |
US20120041028A1 (en) | 2012-02-16 |
ZA200807616B (en) | 2010-07-28 |
CN103058990A (zh) | 2013-04-24 |
EP2004182A1 (en) | 2008-12-24 |
NO20084048L (no) | 2008-10-20 |
US20100280071A1 (en) | 2010-11-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR10314A (es) | Compuestos que tienen actividad en el receptor m 1 y sus usos en medicina | |
GT200500307A (es) | Compuestos quimicos | |
CR10338A (es) | Compuestos pirazolicos heterobiciclicos y metodos de uso | |
GT200900283A (es) | "terapia de combinación con un compuesto actuando como un inhibidor del receptor adp plaquetario". | |
UY30460A1 (es) | Compuestos terapéuticos | |
PA8720801A1 (es) | Nuevas combinaciones terapeuticas para el tratamiento de la depresion | |
UY28766A1 (es) | Compuestos heteropolicíclicos adicionales y su uso como antagonistas del receptor de glutamato metabotrópico | |
UY29735A1 (es) | Piperazinas sustituidas como antagonistas de receptores de glutamato metabotrópicos | |
SV2004001691A (es) | Nuevos derivados de fluoroglicosidos aromaticos, medicamentos que contienen compuestos y sus usos | |
CL2008002793A1 (es) | Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras | |
UY29796A1 (es) | Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor | |
UY29875A1 (es) | Compuestos quimicos | |
ECSP12012326A (es) | Derivados de aminopirimidina como moduladores de la lrrk2 | |
UY27226A1 (es) | Pirazolopirimidinas como agentes terapéuticos | |
CO6311051A2 (es) | Compuestos de pirimidina, composiciones y metodos de uso | |
CR9078A (es) | Derivado de bencimidazol ariloxi-sustituidos | |
CL2009000161A1 (es) | Compuestos derivados de 2,3,4,5-tetrahidro-1h-pirido[4,3-b]indol; composicion farmaceutica que los comprende; uso en el tratamiento de trastornos neurodegenerativos, cognitivos o psicoticos, enfermedad de alzheimer, entre otros; y un kit que contiene a los compuestos. | |
UY30846A1 (es) | Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos | |
PA8567801A1 (es) | Compuestos que modulan la actividad de ppar | |
UA101299C2 (uk) | Сполуки, що мають активність стосовно рецепторів м1, та їх застосування в медицині | |
CU20090058A7 (es) | Compuestos de pirazolina y su uso y composiciones farmacéuticas | |
UY29181A1 (es) | Derivados de bencenosulfonamidas n-sustituidos, composiciones que los contienen, procesos de preparación y aplicaciones | |
ECSP045473A (es) | Derivados de 1-(aminoalquil)-3-sulfonilindol y 1-aminoalquil-3-sulfonilindazol como ligandos de 5-hidroxitriptamina-6 | |
UY30835A1 (es) | 8-alquinilxantinas y derivados | |
UY28870A1 (es) | Derivados heterocíclicos, composiciones y proceso de preparación |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal (granting procedure) |